Article

Difficulty Initiating Sleep Intervention Could Reduce Depressive Symptoms

Author(s):

In a new study, investigators discover insomnia severity could predict first-onset major depressive disorder.

Tessa F. Blanken, MSc

Tessa F. Blanken, MSc

While in the past, researchers have suggested insomnia is a strong modifiable risk factor for major depressive disorder (MDD), the idea of insomnia as a residual symptom of unassessed prior depression or as a comorbid complaint secondary symptom to other depression risks has not been sufficiently addressed.

A team, led by Tessa F. Blanken, MSc, Department of Sleep and Cognition, Netherlands Institute for Neuroscience, examined 768 individuals from the Netherlands Study of Depression and Anxiety who were free from current and lifetime major depressive disorder. Each participant was followed-up for 4 repeated assessments, spanning 6 total years.

The investigators performed separate Cox proportional hazard analyses to evaluate whether baseline insomnia severity, short-sleep duration, and individual insomnia complaints prospectively predicted first-onset MDD during the follow-up period.

The also sorted out whether there were any direct predicative value of individual insomnia complaints among several other complaints that could be associated with insomnia using a novel method of network outcome analysis (NOA).

For the six-year study period, 141 (18.4%) of individuals were diagnosed with first-onset major depressive disorder.

The team found insomnia severity predicted first-onset MDD, but sleep duration did not (HR, 1.11; 95% CI, 1.07-1.15). This was solely driven by the insomnia complaint difficulty initiating sleep (DIS) (HR, 1.10; 95% CI, 1.04-1.16).

Using the novel outcome analysis, the investigators found only DIS directly predicted first-onset MDD, independent of the 4 other associated depression complaints.

“We showed prospectively that DIS is a risk factor for first-onset MDD,” the authors wrote. “Among the different other insomnia symptoms, the specific treatment of DIS might be the most sensible target to combat the global burden of depression through prevention.”

Recent study findings from Johns Hopkins showed that older adults with depression were at a higher risk of remaining depressed if they experienced persistent or worsening sleep problems.

Senior study author Adam Spira, PhD, and colleagues from Johns Hopkins Bloomberg School of Public Health analyzed data from nearly 600 older adults who visited primary care centers in the Northeast US to determine the association between sleep difficulties and outcomes of depression and suicidal ideation.

The team found that adults >60 years old who had a pattern of worsening insomnia symptoms over the following year had almost 30-times the odds of having a major depression diagnosis at the end of the year compared to those who had improving sleep.

The findings suggested that for older adults with depression, insomnia symptoms offered an important clue to their risks for continued depression and suicidal ideation, Spira, a professor in the Department of Mental Health at the Bloomberg School, said in a statement.

Compared with those whose sleep improved, those with worsening sleep were more likely to have a major depression diagnosis (aOR, 28.6; 95% CI, 12.15-67.34), a clinically significant minor depression diagnosis (aOR, 11.88; 95% CI, 5.67-24.89), and suicidal ideation (aOR, 1.1; 95% CI, 1.005-1.199) at one-year follow-up.

Those with worsening sleep were half as likely to achieve remission (aOR, .52; 95% CI, .46-.57).

The study, “Network outcome analysis identifies difficulty initiating sleep as a primary target for prevention of depression: a 6-year prospective study,” was published online in Sleep.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.